MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
Suggest Documents
Vitamin K₂ therapy for postmenopausal osteoporosis.
Etidronate for postmenopausal osteoporosis.
Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.
Postmenopausal osteoporosis.
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
Postmenopausal osteoporosis.
Postmenopausal Osteoporosis.
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Management of postmenopausal osteoporosis.
Risk Factors for Osteoporosis in Postmenopausal Women.
Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy.
Calcitriol or calcium for postmenopausal osteoporosis.
Estrogens and postmenopausal osteoporosis.
Treatment of postmenopausal osteoporosis.
Management of postmenopausal osteoporosis.
New antiresorptive therapies for postmenopausal osteoporosis.
Clinical management of postmenopausal osteoporosis.
Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.
Nitrogen-bisphosphonate therapy is linked to compromised coenzyme Q10 and vitamin E status in postmenopausal women.
Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
Contradicting the evidence for bisphosphonate therapy.
Authorship, institutional and citation metrics for publications on postmenopausal osteoporosis.
Is heritability a risk factor for postmenopausal osteoporosis?
Bisphosphonate therapy for postmenopausal osteoporosis.
Bisphosphonates are agents that are potentially useful for treatment of osteoporosis. They are antiresorptive agents, increasing bone mass by decreasi...
220KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Vitamin K₂ therapy for postmenopausal osteoporosis.
Etidronate for postmenopausal osteoporosis.
Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.
Postmenopausal osteoporosis.
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
Postmenopausal osteoporosis.
Postmenopausal Osteoporosis.
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Management of postmenopausal osteoporosis.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms